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ABSTRACT
Background Mild cognitive impairment (MCI) is
common in early Parkinson’s disease (PD). We evaluated
the stability of PD-MCI over time to determine its clinical
utility as a marker of disease.
Methods 212 newly diagnosed participants with PD
were recruited into a longitudinal study and reassessed
after 18 and 36 months. Participants completed a range
of clinical and neuropsychological assessments. PD-MCI
was classified using Movement Disorders Society Task
Force level I (Montreal Cognitive Assessment <26) and
level II (using cut-offs of 1, 1.5 and 2SD) criteria.
Results After 36 months, 75% of participants
returned; 8% of patients had developed a dementia all
of which were previously PD-MCI. Applying level I
criteria, 70% were cognitively stable, 19% cognitively
declined and 11% improved over 36 months. Applying
level II criteria (1, 1.5 and 2SD), 25% were cognitively
stable, 41% cognitively declined, 15% improved and
19% fluctuated over 36 months. 18% of participants
reverted to normal cognition from PD-MCI.
Discussion Cognitive impairment in PD is complex,
with some individuals’ function fluctuating over time and
some reverting to normal cognition. PD-MCI level I
criteria may have greater clinical convenience, but more
comprehensive level II criteria with 2SD cut-offs may
offer greater diagnostic certainty.
INTRODUCTION
Cognitive impairment in Parkinson’s disease (PD) is
common, ultimately 80% of patients may develop
dementia (PDD).1 Mild cognitive impairment in
PD (PD-MCI) may be a prodromal stage of PDD.
Guidelines to identify PD-MCI have been proposed
by the Movement Disorder Society (MDS).2 The
MDS criteria have yet to be validated, but several
recent studies have investigated the number and
optimal assessments, and best cut-offs to define
PD-MCI.3 4
The MDS PD-MCI guidelines specify that in
order to meet criteria for this diagnosis, a patient
with PD must exhibit gradual cognitive decline
(reported by the patient, informant or clinician)
that is not severe enough to impair functional inde-
pendence or activities of daily living.2 The patient
should not have another primary explanation for
their cognitive impairment such as delirium, stroke,
major depressive disorder or head trauma. The
patient should also not have any other
PD-associated conditions that may significantly
interfere with cognitive testing (eg, motor impair-
ment, severe anxiety, daytime somnolence or
psychosis).
Litvan et al2 classified PD-MCI criteria using
either level I criteria (primarily for use in a clinical
setting) or more stringent level II criteria (primarily
for use in a research setting). Level I criteria require
a less comprehensive battery of tests, for example,
impairment on a global cognitive test which has
been validated in PD such as the Montreal
Cognitive Assessment (MoCA), or impairment on
at least two tests in a limited battery of neuro-
psychological tests. Application of level II criteria
requires at least two neuropsychological tests across
each of five cognitive domains: attention, executive
function, visuospatial function, memory and lan-
guage.2 Patients meeting level II criteria should
either be impaired in two or more tests in one cog-
nitive domain (single domain PD-MCI) or in at
least one test in two or more different domains
(multidomain PD-MCI). Impairment is defined as
performance of 1–2SD below appropriate norms,
significant decline on serial neuropsychological
testing, or a decline from premorbid levels. Level II
criteria also include optional subtype classification:
single domain or multidomain classification as well
as type of impairment.
The longitudinal characteristics of PD-MCI are
unknown, and whether it is a stable state, likely to
decline or even improve over time. A multicentre
study investigating the stability of MCI and demen-
tias found that MCI was associated with diagnostic
uncertainty.5 We hypothesised that PD-MCI may
also be associated with prognostic uncertainty,
which could be problematic in terms of clinical
management, while causing unnecessary distress for
patients. This study sought to determine the stabil-
ity and clinical utility of PD-MCI in newly diag-
nosed patients with PD over 36 months.
METHODS
This study was approved by the Newcastle and
North Tyneside 1 Research Ethics Committee. All
participants provided written informed consent.
Recently diagnosed patients with PD were
recruited from the community and outpatient clinics
in Newcastle and Cambridgeshire, UK as part of
the Incidence of Cognitive Impairment in Cohorts
with Longitudinal Evaluation in PD (ICICLE-PD)
study6 7 and were evaluated at 18-month intervals.
At each assessment, demographic and clinical data
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were collected including MDS Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) Part III, Geriatric Depression Scale
(GDS-15) and levodopa equivalent daily dose (LEDD).8
A detailed schedule of neuropsychological tests was per-
formed at each assessment and has been described previously.6
Attention was assessed using Power of Attention (PoA) and Digit
Vigilance Accuracy from the Cognitive Drug Research Battery.9
Executive function was assessed using the One Touch Tower of
London (OTS) from the Cambridge Neuropsychological Test
Automated Battery (CANTAB),10 phonemic fluency and seman-
tic fluency.11 Memory was assessed using spatial and pattern rec-
ognition memory (SRM and PRM), and paired associate
learning (PAL) subsets from the CANTAB. Visuospatial function
was measured using modified scoring for copying interlocking
pentagons.12 Language was measured using the naming and
language scores from the MoCA.13
We used modified level II criteria to classify PD-MCI as our
study design predated the MDS Task Force PD-MCI criteria
(described by Yarnall et al6). We applied cut-offs of 1.0 (≥1 but
<1.5SD), 1.5 (≥1.5 but <2SD) and 2.0 (≥2SD) SDs below nor-
mative values (controls), or an approximation to the normal dis-
tribution, to classify PD-MCI. We also applied level I PD-MCI
criteria, with cognitive impairment defined as an MoCA score
<26.2 For both criteria, semistructured interviews were con-
ducted with participants and their carers to determine subjective
cognitive symptoms and functional independence. We classified
participants according to the MDS criteria: single domain or
multidomain PD-MCI and the domains impaired (described by
Lawson et al14).
Data were examined for normality, and means were compared
using analyses of variance or Kruskal-Wallis tests as appropriate
(SPSS V.21.0). The χ2 tests were used to compare between-group
distributions of proportion. Cochran’s Q test compared
between-group proportions over time.
RESULTS
Two hundred and twelve newly diagnosed participants with PD
completed baseline assessments; 190 (89.6%) and 158 (74.5%)
returned for 18-month and 36-month evaluations, respectively
(mean of 3.1±0.2 years). Demographic and clinical character-
istics of participants at each time point are presented in table 1.
Participants with cognitive impairment tended to be older, had
completed fewer years of education, and had greater motor
severity and lower global cognition scores (p<0.01 for all).
Figure 1 shows the changes in cognitive classification between
groups at each time point using level II (figure 1A) and level I
(figure 1B) PD-MCI criteria. Between baseline and 18 months,
43% had stable cognition, 30% cognitively declined and 15%
improved in terms of their PD-MCI classification (1 vs 1.5 vs
2SD) using level II criteria. Between 18 and 36 months, 35% of
remaining participants had stable cognition, 29% cognitively
declined and 18% improved (figure 1A). Between baseline and
36 months, 27% (n=58) were cognitively stable, 33% (n=71)
cognitively declined and 14% (n=29) improved; 8% (n=18)
developed PDD.
As shown in figure 1A, the majority of cognitively stable parti-
cipants were classified as normal cognition (PD-CN), with 20%
of participants classified as stable PD-CN at 18 and 36 months.
PD-MCI 2SD was the next most stable group, with 11% and
12% being consistently classified as PD-MCI 2SD at 18 and
36 months, respectively. Nineteen per cent of participants fluc-
tuated over time, with the majority of participants fluctuating
between PD-MCI 1SD, 1.5SD and PD-CN.
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Figure 1 Changes in cognitive classification from baseline to 36 months. (A) Change in cognitive classification using MDS PD-MCI level II criteria
to classify PD-MCI using cut-offs of 1, 1.5 and 2SD. (B) Change in cognitive classification using MDS PD-MCI level I criteria to classify PD-MCI using
MoCA score. Twenty-three participants did not complete MoCA at baseline and were excluded from this analysis. Percentages relate to the
proportion of participants evaluated at that time point: baseline, 18 or 36 months. MDS, Movement Disorders Society; MoCA, Montreal Cognitive
Assessment; PD-CN, Parkinson’s disease with normal cognition; PD-MCI, mild cognitive impairment in Parkinson’s disease; PDD, Parkinson’s disease
dementia.
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Some participants reverted to PD-CN at 18 (8%) and
36 months (10%) having previously been classified as PD-MCI
(cumulatively 18%), although this is <1% at each time point
when applying PC-MCI 2SD criteria. Reverters were signifi-
cantly younger than non-reverters (61.3±9.6 vs 68.2±9.2 years,
respectively, p<0.01) and at baseline had better neuropsycho-
logical scores for phonemic and semantic fluency, OTS, PoA,
PRM and PAL (p<0.05 for all). There were no significant dif-
ferences between reverters and non-reverters in terms of pre-
morbid IQ, motor severity, LEDD, GDS-15 or anticholinergic
use (p>0.05 for all).
PD-MCI subtypes were examined. At baseline, 78% (n=109)
were multidomain PD-MCI, while the remaining 22% (n=30)
had single domain impairment. The number of multi domains
impaired ranged from two to five; 51% were impaired in two
domains, 25% in three domains, two participants were impaired
in four domains and only one was impaired in all five domains.
Executive function was the most commonly impaired domain
(59%), followed by memory (51%), attention (35%), language
(31%) and visuospatial function (24%). Of those diagnosed
with PDD, only 3 had single domain PD-MCI at baseline; 16
had impaired executive function at baseline, 12 had impaired
visuospatial function, 11 had impaired memory, and 8 had
impaired attention while only 5 had impaired language.
Using PD-MCI level I criteria (figure 1B), a greater propor-
tion of participants were classified as PD-CN compared with
level II criteria at baseline, 18 and 36 months (59% vs 34%,
χ2=26.7, p<0.001; 61% vs 32%, χ2=40.1, p<0.001; and 62%
vs 35%, χ2=35.4, p<0.001, respectively). Between baseline and
18 months, 68% of participants were stable, 12% cognitively
declined and 10% improved using PD-MCI level I criteria; 56%
of the remaining participants were stable between 18 and
36 months with 16% showing cognitive decline and 7% improve-
ment. Over 36 months, 51% (n=95) were cognitively stable,
13% (n=25) cognitively declined and 8% (n=15) improved.
PD-MCI level I and II criteria classification accuracy was com-
pared using baseline data; PD-MCI 2SD was used to define
PD-MCI as it had greater diagnostic stability. In total, 53.2%
(n=100) and 16.0% (n=30) were identified as PD-CN and
PD-MCI, respectively, using both criteria. Data revealed that
5.9% (n=11) of those defined with level I criteria were false-
positive classifications while 25.0% (n=47) were false-negative
classifications (χ2=22.5, p<0.001). Of those who developed
PDD, all participants were identified as PD-MCI using level I
criteria and 15 (83%) were identified using level II criteria with
a 2SD cut-off.
DISCUSSION
To the best of our knowledge, this is the first study to investigate
the stability of PD-MCI using MDS level I and II criteria over
time. Using level II criteria, we found that more than a quarter
of participants were cognitively stable over 36 months, one-third
cognitively declined and 14% improved. Eight per cent of
participants developed PDD, of whom most were previously
classified as PD-MCI 2SD. We also found that more than three-
quarters had multidomain impairment, and 83% of PDD parti-
cipants had multidomain impairment at baseline.
Our results show that the operational definition of PD-MCI is
an important consideration. Using level I criteria may be more
clinically convenient—it is quick to administer and, as our
results show, comparably stable. We applied an MoCA score of
<26 plus subjective cognitive decline to classify PD-MCI, which
gave a reasonable indication of patients who had PD-MCI. We
did not use the MMSE to classify cognitive impairment as
previous studies have suggested that the psychometric properties
of the MMSE are not sensitive to PD-MCI.15 16
However, one-quarter of patients were subject to type I error
using level I criteria compared with using the more comprehen-
sive level II criteria and stricter cut-offs. We used a schedule of
11 cognitive assessments across five cognitive domains with
cut-offs of 1, 1.5 and 2SD, below normative values; using the
2SD cut-off gave greater diagnostic certainty. One study with a
smaller sample size (n=76) found that using a 1.5SD PD-MCI
cut-off, 13% of participants improved, 3% fluctuated and 22%
cognitively declined.17 In comparison, our data showed that a
greater proportion of participants fluctuated (19%), the majority
of whom were classified as PD-MCI using a 1 or 1.5SD cut-off,
whereas a 2SD cut-off was more stable. This could suggest that
PD-MCI 2SD has greater diagnostic certainty. A previous study
suggested that 2SD below normative values had optimal sensitiv-
ity and specificity compared with 1 or 1.5SD.3
We demonstrated that 7–10% of patients classified as
PD-MCI reverted back to normal at 18 and 36 months (18%
cumulatively), although this rate was much lower using a more
conservative 2SD cut-off. A prospective study found a similar
conversion rate of MCI to normal cognition (9%) in partici-
pants with persistent PD-MCI at time of diagnosis compared
with 3-year follow-up.18 Reversions to normal cognition from
PD-MCI may be due to a learning effect, an effect of medication
or normal fluctuations in cognition.7 In a non-PD population,
38% of people with MCI reverted to normal cognition over a
median of 5.1 years; fewer participants reverted if they had
amnestic MCI or multidomain MCI and poorer cognitive func-
tion.19 Poorer cognitive functioning in non-reverters is consistent
with the findings of our study; we found that fewer participants
reverted if they had multidomain PD-MCI and were impaired in
executive function. Roberts et al19 reported that reverters were
nearly seven times more likely to later develop MCI or dementia
than those with baseline normal cognition, suggesting that MCI
at any time point may have prognostic utility.
The strengths of this prospective study are its longitudinal
design, the use of an incident cohort of community-
representative patients with PD, and the comprehensive sched-
ule of neuropsychological tests used. As with any longitudinal
study, missing data were an issue. This has implications for clas-
sification of PD-MCI and could result in a type II error classifi-
cation of some participants. However, we examined differences
between participants at baseline and those with missing data
were found to be representative of the whole sample.7 A small
number of participants did not return for further assessments;
these participants may have been pertinent to the findings of
this study as they may have had more rapid decline in terms of
cognition and disease progression. However, there were no sig-
nificant differences in baseline scores. Age and education are
factors that may affect cognition. We examined the scores and
cut-offs for cognitive tests using age and education as covariates.
However, remodelling our data did not have a significant impact
on PD-MCI classification.
In conclusion, we have shown that PD-MCI is complex and
subject to fluctuation over time, which increases diagnostic
uncertainty. PD-MCI level I criteria may have greater clinical
utility but more comprehensive level II criteria with 2SD cut-offs
provide greater prognostic utility. We propose that clinicians
could apply level I criteria using an MoCA score of <26, which
would help to identify PD-MCI, and would have some prognos-
tic value in identifying patients at risk of developing PDD.
However, clinicians should be cautious when using the MMSE
as scores may not be sensitive to cognitive impairment in PD.
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